Saffron for Sleep: What Questionnaires and Wrist Recordings Found

These three saffron trials tested named extract preparations, rather than saffron used in cooking or tea.¹²³

The wrist-recording trial did not show longer recorded sleep

The 2021 Belgian trial¹ randomized 66 adults, with 59 included in the per-protocol analysis. Participants took a 15.5 mg Saffr’activ preparation or placebo each evening for six weeks, and wore wrist actimeters during three recording weeks.¹

Time in bed increased by about 14 minutes with saffron and fell by about nine minutes with placebo, using the paper’s table values. Recorded sleep duration, sleep efficiency and time to fall asleep did not significantly separate the groups. Neither did the primary Leeds Sleep Evaluation Questionnaire results.¹

One participant stopped saffron after evening palpitations, which resolved after stopping. Comercial Quimica Massó funded the research and participated in study design and manuscript preparation. The findings do not establish that spending longer in bed improved sleep itself.¹

The 2025 trial’s main positive comparison pooled two doses

The 2025 German study² randomized 165 adults to 20 mg Safr’Inside, 30 mg or placebo nightly for four weeks. Its main reported analysis included 158 participants, predominantly women. Diagnosed sleep apnea and chronic sleep disorders lasting more than a year were among the exclusions.²

On the 0-to-24 Athens Insomnia Scale, the adjusted advantage for the two saffron groups combined was about 0.95 points over placebo. Neither individual dose significantly beat placebo on that endpoint after adjustment for multiple comparisons. A separate weekly sleep-quality rating favored both doses, but all measurements were questionnaires, without wrist recordings or a sleep study.²

Activ’Inside funded and helped design the study, with editorial input; the academics reported independent analysis. The pooled difference does not establish a cure.²

The 2026 women’s trial measured daytime impairment separately

In June 2026, researchers reported a 12-week trial of 86 women aged 50 to 70 with low mood and poor sleep, using 28 mg Affron daily or placebo. Depression was the primary outcome; sleep outcomes were exploratory, without adjustment for multiple testing.³

The sleep-related impairment score favored saffron; the sleep-disturbance score did not, with a between-group P value of 0.786. This does not demonstrate a general improvement in sleep. Pharmactive supplied and funded the product and participated in the initial concept and design.³

The extract and the safety record still matter

The FDA does not approve dietary supplements before marketing. It advises discussing a proposed supplement with a doctor or pharmacist because interactions with medicines or other supplements are possible. Bring the full label, including the extract name, amount per serving and any added sleep ingredients.⁴

Ask the manufacturer for information beyond the label if the preparation is unclear. A study of one extract does not independently verify the contents of the bottle you are considering. The FDA does not routinely test supplements before sale.⁴

Define the sleep problem before choosing the purchase

The “Read the Research Without Becoming the Researcher” section of Did I Do That in My Sleep? asks readers to identify what each source can support. For a sleep product, separate difficulty falling asleep, time awake during the night, morning refreshment and daytime impairment. Record which one you want help with.

For long-term insomnia, the National Heart⁵, Lung, and Blood Institute describes CBT-I as the usual first treatment, commonly delivered over six to eight weeks, in person, by phone or online. Our insomnia and CBT-I guide explains that approach. Supplement findings do not establish an alternative with comparable benefits.⁵